The COVID-19 pandemic may have had an effect on treatment approaches for patients with multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.
Robert M. Rifkin, MD, FACP — medical oncologist and hematologist at Rocky Mountain Cancer Centers, disease lead for multiple myeloma for The US Oncology Network and medical director for biosimilars at McKesson — spoke with Healio about the findings and their implications.
Rifkin also spoke about the insights registries like the Connect MM Registry can provide to inform treatment.
